66947-92-0

Basic information

• Product Name: 2-AMINO-BENZOTHIAZOLE-6-CARBOXYLIC ACID METHYL ESTER
• Synonyms: VITAS-BB TBB000629;AKOS BBS-00000328;AKOS BC-3185;2-AMINO-BENZOTHIAZOLE-6-CARBOXYLIC ACID METHYL ESTER;METHYL 2-AMINO-1,3-BENZOTHIAZOLE-6-CARBOXYLATE;IFLAB-BB F1981-0014;ASISCHEM D29190;6-Benzothiazolecarboxylicacid,2-amino-,methylester(9CI)
• CAS NO: 66947-92-0
• Molecular Formula: C₉H₈N₂O₂S
• Molecular Weight: 208.24
• Product Categories: BENZOTHIAZOLE
• Mol File: 66947-92-0.mol

Chemical Properties

• Melting Point: 244-246
• Boiling Point: 378.4 °C at 760 mmHg
• Flash Point: 182.6 °C
• Appearance: /
• Density: 1.422
• Vapor Pressure: 6.31E-06mmHg at 25°C
• Refractive Index: 1.699
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.74±0.10(Predicted)
• CAS DataBase Reference: 2-AMINO-BENZOTHIAZOLE-6-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-BENZOTHIAZOLE-6-CARBOXYLIC ACID METHYL ESTER(66947-92-0)
• EPA Substance Registry System: 2-AMINO-BENZOTHIAZOLE-6-CARBOXYLIC ACID METHYL ESTER(66947-92-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 66947-92-0(Hazardous Substances Data)

Usage

Uses

Used in Dye Industry:
2-AMINO-BENZOTHIAZOLE-6-CARBOXYLIC ACID METHYL ESTER is used as a reactant in the preparation of azo-metal chelate dyes. It plays a crucial role in the synthesis of these dyes, which are known for their colorfastness, brightness, and resistance to fading. These dyes are widely used in various applications, including textiles, plastics, and printing inks, due to their superior properties and performance.

InChI:InChI=1/C9H8N2O2S/c1-13-8(12)5-2-3-6-7(4-5)14-9(10)11-6/h2-4H,1H3,(H2,10,11)

Upstream product

• 1147550-11-5 ammonium thiocyanate 
• 619-45-4 4-methoxycarbonyl aniline 
• 333-20-0 potassium thioacyanate 
• 67-56-1 methanol 
• 93-85-6 2-aminobenzothiazole-6-carboxylic acid 
• 540-72-7 sodium thiocyanide 
• 73931-63-2 methyl 1,3-benzothiazole-6-carboxylate 
• 3425-46-5 potassium selenocyanate 

Downstream Products

• 90792-69-1 2-chlorobenzo[d]thiazole-6-carboxylic acid methyl ester 
• 1070908-14-3 2-(2-morpholin-4-yl-ethylamino)-benzothiazole-6-carboxylic acid [2-methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide 
• 1070908-55-2 2-(5-fluoro-pyridin-2-ylamino)-benzothiazole-6-carboxylic acid [2-methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide 
• 1070908-62-1 2-chloro-benzothiazole-6-carboxylic acid [2-methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide 
• 14543-45-4 4-amino-3-mercaptobenzoic acid 
• 1620069-94-4 C₂₇H₂₀N₃O₅S^(1-)*Na⁽¹⁺⁾ 
• 1620069-92-2 C₂₇H₂₁N₃O₅S 
• 1620074-46-5 C₂₈H₂₃N₃O₅S 
• 1428621-61-7 methyl 2-[2-(4-methylbenzoylimino)-6-(phenylcarbamoyl)benzo[d]thiazol-3(2H)-yl]butanoate 
• 1428621-60-6 2-(4-methylbenzamido)-N-phenylbenzo[d]thiazol-6-carboxamide 
• 1428621-57-1 2-(4-methylbenzamido)benzo[d]thiazol-6-carboxylic acid 
• 1428621-58-2 methyl 3-(1-methoxy-1-oxobutan-2-yl)-2-(4-methylbenzoylimino)-2,3-dihydrobenzo[d]thiazol-6-carboxylate 
• 955569-38-7 methyl 2-(4-methylbenzamido)benzo[d]thiazol-6-carboxylate 

Relevant articles and documents

Iodine-catalyzed amination of benzothiazoles with KSeCN in water to access primary 2-aminobenzothiazoles

A facile and sustainable approach for the amination of benzothiazoles with KSeCN using iodine as the catalyst in water has been disclosed under transition-metal free conditions. The reaction proceeded smoothly to afford various primary 2-amino benzothiazoles in up to 96% yield. A series of control experiments were performed, suggesting a ring-opening mechanism was involved via a radical process. This protocol provides efficient synthesis of primary 2-aminobenzothiazoles

Benzothiazolyl ureas are low micromolar and uncompetitive inhibitors of 17Β-HSD10 with implications to Alzheimer’s disease treatment

Human 17β-hydroxysteroid dehydrogenase type 10 is a multifunctional protein involved in many enzymatic and structural processes within mitochondria. This enzyme was suggested to be involved in several neurological diseases, e.g., mental retardation, Parkinson’s disease, or Alzheimer’s disease, in which it was shown to interact with the amyloid-beta peptide. We prepared approximately 60 new compounds based on a benzothiazolyl scaffold and evaluated their inhibitory ability and mechanism of action. The most potent inhibitors contained 3-chloro and 4-hydroxy substitution on the phenyl ring moiety, a small substituent at position 6 on the benzothiazole moiety, and the two moieties were connected via a urea linker (4at, 4bb, and 4bg). These compounds exhibited IC50 values of 1–2 μM and showed an uncompetitive mechanism of action with respect to the substrate, acetoacetyl-CoA. These uncompetitive benzothiazolyl inhibitors of 17β-hydroxysteroid dehydrogenase type 10 are promising compounds for potential drugs for neurodegenerative diseases that warrant further research and development.

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, and metabolism of lipid and glucose and becomes a promising therapeutic target for nonalcoholic steatohepatitis (NASH) or other FXR-dependent diseases. The phase III trial results of obeticholic acid demonstrate that the FXR agonists emerge as a promising intervention in patients with NASH and fibrosis, but this bile acid-derived FXR agonist brings severe pruritus and an elevated risk of cardiovascular disease for patients. Herein, we reported our efforts in the discovery of a series of non-bile acid FXR agonists, and 36 compounds were designed and synthesized based on the structure-based drug design and structural optimization strategies. Particularly, compound 42 is a highly potent and selective FXR agonist, along with good pharmacokinetic profiles, high liver distribution, and preferable in vivo efficacy, indicating that it is a potential candidate for the treatment of NASH or other FXR-dependent diseases.

1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation

Glycogen synthase kinase 3 (GSK-3)has become known for its multifactorial involvement in the pathogenesis of Alzheimer's disease. In this study, a benzothiazole- and benzimidazole set of 1-aryl-3-(4-methoxybenzyl)ureas were synthesised as proposed Cys199-targeted covalent inhibitors of GSK-3β, through the incorporation of an electrophilic warhead onto their ring scaffolds. The nitrile-substituted benzimidazolylurea 2b (IC50 = 0.086 ± 0.023 μM)and halomethylketone-substituted benzimidazolylurea 9b (IC50 = 0.13 ± 0.060 μM)displayed high GSK-3β inhibitory activity, in comparison to reference inhibitor AR-A014418 (1, IC50 = 0.072 ± 0.043)in our assay. The results suggest further investigation of 2b and 9b as potential covalent inhibitors of GSK-3β, since a targeted interaction might provide improved kinase-selectivity.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

FXR regulator with spirane structure

The invention provides a new compound which has certain agonist activity on a Farnesoid X receptor (FXR) and is used for treating FXR mediated diseases and/or symptoms such as liver disease and gastrointestinal disease. (The formula is shown in the description.).

Chrysin-benzothiazole conjugates as antioxidant and anticancer agents

7-(4-Bromobutoxy)-5-hydroxy-2-phenyl-4H-chromen-4-one, obtained from chrysin with 1,4-dibromobutane, was combined with a wide range of 6-substituted 2-aminobenzthiazoles, which had been prepared from the corresponding anilines with potassium thiocyanate. Free radical scavenging efficacies of newer analogues were measured using DPPH and ABTS assays, in addition to the assessment of their anticancer activity against cervical cancer cell lines (HeLa and CaSki) and ovarian cancer cell line (SK-OV-3) implementing the SRB assay. Cytotoxicity of titled compounds was checked using Madin-Darby canine kidney (MDCK) non-cancer cell line. Overall, 6a-r indicated remarkable antioxidant power as DPPH and ABTS+ scavengers; particularly the presence of halogen(s) (6g, 6h, 6j-6l) was favourable with IC50 values comparable to the control ascorbic acid. Unsubstituted benzothiazole ring favored the activity of resultant compounds (6a and 6r) against HeLa cell line, whereas presence of chlorine (6g) or a di-fluoro group (6k) was a key to exert strong action against CaSki. Moreover, a mono-fluoro (6j) and a ketonic functionality (6o) were beneficial to display anticipated anticancer effects against ovarian cancer cell line SK-OV-3. The structural assignments of the new products were done on the basis of IR, 1H NMR, 13C NMR spectroscopy and elemental analysis.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES

This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.